Ozempic, a patent challenge, and the $25 billion race for India's weight-loss drug market

Mumbai: In late May, Dr. Reddy's Laboratories, a pharmaceutical company from Hyderabad, sprang a surprise. It filed a patent challenge against Novo Nordisk, a Danish company, for its popular weight loss drug semaglutide.
Novo Nordisk filed for two patent applications in India—in 2006, which expired in September 2024, and another in 2007, which is set to expire in March 2026. Dr. Reddy's has challenged the second patent, contending that it lacks novelty.
Pharma companies often file follow-on patents with claims of modifications to the original compound and its derivative forms. The follow-on patents allow drug developers to extend their market monopoly and halt generic competition for longer. Generic versions are cheaper copies of the original drug.
Dr. Reddy's, obviously, is in a hurry to launch a generic version. A win for the company will upend the plans of more than a dozen local pharmaceutical firms, all of whom are eyeing a slice of the estimated $25 billion Indian weight loss market.
No prescription drug in recent memory has captured the imagination of Indian patients as much as semaglutide. Or for that matter globally. In 2024, sold under three brand names—Ozempic, Wegovy and Rybelsus—semaglutide is the second most prescribed drug in the world, notching sales of $29 billion annually.
A more recently launched competing brand, Mounjaro, by US-headquartered drug maker Eli Lilly, grew 123% in 2024 to $11.5 billion and is already among the top 10 drugs in the world, according to Drug Discovery & Development, a pharmaceutical industry news website.
'It's a big opportunity. It's a product that comes once in a while in the pharma cycle, and perhaps a product that people are a lot more aware of, much before its launch," Umang Vohra, managing director and global CEO of Cipla, told journalists during an interaction last month.
Social media has contributed immensely to the street popularity of Ozempic, largely driven by celebrity endorsements by the likes of Oprah Winfrey and Elon Musk. Both admitted to using such drugs to manage their weight. Though Indian celebrities haven't yet admitted to their use, the mystery slimming of Bollywood film maker Karan Johar and TV talk show host Kapil Sharma have drawn comparisons.
Opportunity 2.0
Nonetheless, it is not all social media. There is a genuine market for weight loss medications—numbers tell the story.
A recent Lancet study stated that India is expected to total 450 million overweight or obese people by 2050, the largest in the world. The study also found that obesity rates increased from 1.2% in 1990 to 9.8% in 2022 for women and 0.5% to 5.4% in men. Those with body mass index (BMI) between 25 kg/m2 to 29.9 kg/m2 are considered overweight while those with an index of over 30 kg/m2 are considered obese.
'Often, lifestyle diseases are associated with adults but we must not overlook the increasing issues of overweight and obesity in juveniles. It is a growing menace," said Dr Sambit Patnaik, a Mumbai-based surgeon.
The pharmaceutical industry has also spotted a rare opportunity, similar to the one it saw in anti-diabetic drugs at the turn of the century. At that time, the Indian pharmaceutical market, according to market research agency MARG, was all of ₹16,000 crore and diabetic drugs accounted for about ₹1,000 crore of it. Today, the market for diabetic drugs is worth ₹40,000 crore and it accounts for roughly 10% of the ₹4 trillion Indian industry.
Back then, the boom was aided by the generic version of metformin, an oral drug with lower gastric side effects for type 2 diabetes. It caught the fancy of Ranbaxy Laboratories, Dr. Reddy's, Glenmark Pharmaceuticals and a host of other Indian pharmaceutical companies.
Like diabetes drugs, weight loss medications also have to be taken as long as a patient wants to manage her or his weight—which explains the current gold rush.
Crash the price
In India, generic versions can cut current prices substantially, thereby expanding the market.
Novo Nordisk's Rybelsus is available in India but only in oral form and a month's supply costs ₹10,000. The most effective form of the drug is as an injectable, and it is delivered in metered doses using a pen-like device with thin hair like needles. Imports can cost upwards of ₹80,000 per month. The injectable version is expected to launch soon.
Despite the high costs, Rybelsus sales have notched up ₹418 crore, between its launch in 2022 and March 2025, according to Pharma data agency IQVIA.
Mounjaro's injectables, available in India, cost far less— ₹17,500 per month.
'Since India sells branded generic dosages, the retail price of new launches will be 40-70% of the innovator's price," Ravinder Singha, managing director of Firmlink Pharma, a generic exporter, said. 'But since Mounjaro is the benchmark treatment, we should expect semaglutide drugs to be substantially cheaper," he added.
Semaglutide tablets, therefore, could be available for ₹4000- ₹7000 per month and Wegovy clones at a bigger discount to Mounjaro's ₹17,500 per month.
'Generic brands in India will hit the shelf the next day a drug goes off patent," said Nimish Mehta, founder of Research Delta Advisors, a pharma consultancy.
So, Indian generics should be available from April 2026 onwards.
Meanwhile, Indian pharmacies have acknowledged the growing demand for such drugs.
'These GLP-1s…everyday we are selling huge quantities," Shobana Kamineni, executive chairperson of Apollo Health Co and Apollo Pharmacies, said.
Medications used to treat obesity and type 2 diabetes are classified as GLP-1 (glucagon-like peptide-1) drugs.
The science
GLP-1 is an equivalent of peptide glucagon that is produced in the small intestine and colon after ingestion of food which increases blood sugar. Glucagon then stimulates the pancreas to produce insulin to control blood sugar.
GLP-1 drugs behave like synthetic glucagon and stimulate the same effects from the body. In addition, GLP-1 drugs leave the user with a feeling of fullness that sends a message to the brain to slow down the ingestion of food.
From the last decade, there is enough evidence that the new class of GLP-1 drugs, like semaglutide and tirzepatide, offer weight reduction between 21-23% of the initial body weight without any severe side effects. And as anti-diabetic drugs, they were meant for prolonged use. 'In the range of medication for management of obesity, (GLP-1s) have proven to be the game changer," bariatric surgeon Dr Muffazal Lakdawala told Mint.
Historically, GLP-1 class of drugs did not see much competition for two reasons. Initially, these drugs were marketed as an anti-diabetic injection—there were already many competing drugs available in that space.
Second, glucagon being a peptide hormone, an organic substance, the drugs had to emulate their form and structure. Like insulin, they can be produced by fermentation or by chemical synthesis and both have their complexities. Producing large quantities of fermentation medicines like insulin or penicillin require high investments, both in manufacturing and cold supply chains.
Even in the oral version of semaglutide, which is manufactured by chemical synthesis, the manufacturing process is a long and complex one. Oral delivery of peptides does not permeate the gastrointestinal tract easily and, therefore, Novo Nordisk had to engineer its product differently to ensure potency.
US dreams
Despite all the complexities, Indian companies want to grab the opportunity the US, global and Indian markets present. Let's look at the US first.
Companies like Sun Pharma, Dr. Reddy's, Lupin and Natco Pharma (which has a tie-up with Mylan Pharmaceuticals) filed applications with the US Food and Drug Administration (FDA) to make the generic versions of semaglutide the same month—December 2021. They did so to avail what is called the first-to-file (FTF) status. Overall, 18 Indian companies have applied.
Generic applications in the US are filed way before patents expire and an FTF allows a company to market its generic for 180 days exclusively in the US, before more cheaper generics hit the market.
Natco (through Mylan) is the only company to have sought approval for generic Wegovy.
The US FDA has not yet approved any generic so far.
'Since an application to the FDA will include a sample of the product and details of manufacturing plants, we can assume that there is enough confidence among Indian players to make the drug," Mehta of Research Delta Advisors said.
India stack
A long list of companies, from different pharma sub-sectors, could benefit from the weight-loss bonanza.
For the domestic market and for generic exports to countries where no patents exist, the list of companies waiting to launch semaglutide next year includes Dr. Reddy's, Sun Pharma, Cipla, Zydus Lifesciences, Lupin, Mankind Pharma, Alkem Laboratories, Biocon, Aurobindo Pharma, Natco and Torrent Pharmaceuticals among others.
Zydus Lifesciences is working on a single pen device in multiple strengths, The Economic Times reported last month. It is also working on a novel formulation for semaglutide to commercialize in India and other markets. 'We are on track for day one launch in India," managing director Sharvil Patel told investors during an earnings call last month.
Cipla, meanwhile, is eyeing the launch of GLP-1s through partnerships as well as through its own generic version. In a post-earnings media interaction recently, the company's managing director and global CEO Umang Vohra said: 'I think the biggest opportunity for us, at least, would continue to be the Indian market."
Biocon has already launched another GLP-1, liraglutide, in India earlier this month. 'Our strategy is to offer liraglutide at competitive prices, aligned with local healthcare economics to maximize patient access in India," a company spokesperson told Mint in an email response.
Biocon plans to launch semaglutide in India mid-next year, CEO Siddharth Mittal had told Mint in an earlier interview. The company now plans to expand its manufacturing capabilities to ensure supply reliability, it said in the emailed response.
Sun Pharma and Mankind are also working on their own novel anti-obesity drugs. Sun Pharma is working on a novel GLP-1 GL0034 called utreglutide, which will likely be commercialized by the end of this decade.
Mankind's drug candidate, GRP119, is currently in phase 2 trials in Australia. For the generic version of semaglutide, the company is banking on its salesforce and reach to give it a competitive edge, managing director Rajeev Juneja told Mint in an earlier interview.
'Any doctor would want to prescribe it, because now people know that there is something called Mounjaro, or semaglutide or Ozempic," Juneja said. 'We, by default, have a natural advantage because we have the deepest coverage, we have the maximum number of people working in each division," he added.
Further, players like Divi's Laboratories, a manufacturer of active pharmaceutical ingredients, and Syngene International, a contract research, development and manufacturing company, can also benefit from the gold rush.
'Divi's Laboratories will be a key beneficiary in GLP-1 manufacturing as it makes several components in the peptide sequence," Shrikant Akolkar, head of pharmaceutical research at Nuvama, a brokerage, said.
OneSource Specialty Pharma, the contract development and manufacturing arm of Strides Pharma, is among the few companies with end-to-end capabilities for GLP-1s—from formulation to device assembly. 'The most complex part of the whole value chain is to assemble the pen devices," OneSource Pharma's CEO, Neeraj Sharma, told Mint during a recent interaction.
Another company, Vadodara-based Shaily Engineering Plastics, says it is nearly doubling its manufacturing line to make injectable pens—from 45 million to 85 million—funded by customer advances.
A caution
Clearly, speed to market will separate the winners from the also-rans.
'Early movers among the Indian players stand a good chance to benefit from GLP-1," said Akolkar. A recent report by Nuvama put a buy on Dr. Reddy's and Divi's Laboratories and a hold on Natco Pharma based on their GLP-1 play.
Nonetheless, some doctors fear misuse of the drug because of its popularity.
A prescription for diabetic drugs can be written by any medical practitioner. Weight loss clinics in the unorganised sector could start dispensing the drug for cosmetic purposes. For instance, a person in her 20s, who is slightly overweight, may be tempted to use these drugs instead of trying to lose weight by making lifestyle changes.
'We need some regulations to prevent over-the-counter use for weight loss," Dr Muffazal Lakdawala said. 'It is a hormonal drug so you have to be a little careful."

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Economic Times

35 minutes ago

• Economic Times

UAE rule, wary I-T to deter dodgy crypto deals

Mumbai: In the lane to launder money, the skill to move cryptos to control companies and properties in Dubai has been honed over the past few years. But treading that alley would soon become tougher. Dual, albeit unrelated, developments in India and the UAE would force money movers to devise new tricks. First, Income tax (I-T) officials, hunting for illicit homes of Indians over the past six months, now strongly suspect that some property purchases were made with cryptocurrencies; second, a new regulatory regime in the Middle East country, would soon end payment in cryptos, other than stable coins, to freely buy goods and services. "When Indian residents use crypto to purchase real estate, they bypass Indian banking channels and FEMA scrutiny. But, under the new UAE regulations (expected from August), merchants would no longer accept crypto directly. Only entities licensed by the UAE Central Bank would be allowed to convert stablecoins to AED after collecting full KYC. While this framework ensures the buyer's identity is recorded, it remains unclear whether such data would be shared under the India-UAE tax treaty," said Purushottam Anand, founder of the law firm Crypto raiding a leading UAE developer having roots in Mumbai and clients across India, a northern office of the I-T department found that more than 460 buyers in the 650-odd property deals have no record of having remitted money through banks to acquire the properties. According to findings which were shared with other I-T centres two months ago, the arm of the UAE realtor which brokered the deals was aided by a network of 86 sub-brokers who later shared details with the tax office. According to tax circles, some of the clients had paid in cryptos, probably under the belief it would go untraced. Earlier this year, the department had found that hundreds of mule accounts were opened by a few persons in Kerala to deposit cash, use the money to buy cryptos -either on local platforms or through peer-to-peer transactions-and then move the coins to other wallets before encashing the them in UAE, or buying assets like properties, or transferring them to third parties. "When digital assets move from exchanges to P2P platforms or private wallets, monitoring becomes difficult, creating opportunities for illegal activities such as ransomware attacks, laundering, tax evasion, and potentially terrorist financing. Although the exchanges are required to report 'suspicious transactions', including withdrawals, with the Financial Intelligence Unit-India, such risks can be further addressed through stricter enforcement of TDS provisions, i.e. Sections 194S or 195, ensuring tax compliance for all crypto transactions, whether conducted on or off exchanges. Additionally, specifying the reporting entities and the format for disclosures under Section 285BAA will improve traceability," said Ashish Karundia, founder of the CA firm Ashish Karundia & Co. 'PAYMENT TOKEN REGULATIONS' The new 'Payment Token Services Regulation' lays down the rules and conditions established by the UAE Central Bank for granting a licence or registration for payment token services-which include payment token issuance, token conversion, and token custody and transfer. Under the rules no merchant or anyone in the UAE selling goods or services can accept a virtual asset unless it's a dirham payment token issued by a licensed issuer. Also, a bank cannot act as a payment token issuer. UAE is working on Dirham-linked stable coin (like USDT or Tether which is pegged to the dollar)."This would have implications for India which has close economic and financial ties with the UAE. By bringing digital assets such as payment tokens under a structured licensing and anti-money laundering framework, the regulation adds a layer of safety and transparency to cross-border digital financial flows. For Indian individuals and businesses engaging in the UAE's digital economy, on one hand this means greater clarity, reduced risk of fraud, and alignment with global best practices; on the other hand, the clear prohibition on anonymous crypto instruments like privacy tokens reinforces the global trend toward traceable and regulated digital transactions. This is something India is also actively pursuing through its own financial intelligence mechanisms. This would deter transactions in property, high value luxury products bought by Indians in UAE using crypto tokens," said Siddharth Banwat, partner at CA firm Banwat & Associates dealers said the UAE rules are not entirely fool-proof as coins can be routed through platforms in multiple jurisdictions whose cooperation would be vital to spot the trail. But the very presence of licensed intermediaries collecting and storing information would deter money movers.

Business Standard

an hour ago

• Business Standard

Epsilon to challenge China's dominance in EV battery cell materials

May set up ₹9K cr plant for making 100K tonnes of graphite anode Surajeet Das Gupta New Delhi Listen to This Article Rare earth magnet is not the only area where the Chinese dominate the world. They also control two other crucial areas of electric vehicle (EV) battery cell — manufacturing of graphite anode, required for lithium-ion batteries, as well as cathode powder, to make lithium iron phosphate (LiFePO4 or LFP) battery. LFP batteries go into buses and commercial vehicles (CVs), and are considered safer. But an Indian company, Epsilon Advanced Materials, is trying to break into the market. It has finalised plans to set up a plant to manufacture these in Karnataka. To begin with, it is setting up a 100,000

Business Standard

an hour ago

• Business Standard

Rajiv Sharma Named India's Top Sales Trainer, Transforming Corporate Sales Teams by Global Gurus

VMPL New Delhi [India], June 20: In a landmark recognition for India's sales training landscape, Rajiv Sharma, Founder and Program Director of NLP Limited, has been named among the Top 5 Global Sales Trainers, solidifying his position as India's leading authority on sales transformation. Sharma, a veteran leadership coach, corporate trainer, and creator of the acclaimed MARK Model, has helped over 850,000 professionals across 52 countries reinvent their approach to sales, customer influence, and business growth. His methodologies are now being adopted by Fortune 500 companies, high-growth start-ups, and public sector enterprises across India. As organizations across Pune, Mumbai, Delhi, Ahmedabad, and Bangalore navigate a more competitive post-pandemic economy, Sharma's result-oriented frameworks are being credited with turning around underperforming teams, lifting conversion rates, and boosting revenue by up to 40% in just six months. A New Standard in Sales Training "Sales training in India has traditionally been skills-based," Sharma commented in a recent leadership forum. "But what drives lasting impact is when we train identity, not just ability. That's when confidence takes root. That's when revenue follows." What sets Sharma apart, according to industry insiders, is his fusion of Neuro-Linguistic Programming (NLP) with high-performance sales strategies. His training programs incorporate subconscious alignment techniques, behavioral simulations, and consultative selling principles--reshaping how Indian sales professionals think, feel, and close deals. From Struggling Sales to Strategic Selling Across sectors--from banking and insurance to real estate, FMCG, and IT--companies are reporting measurable outcomes. These include increased client retention, improved Net Promoter Scores (NPS), and significant growth in high-ticket sales. "Rajiv's programs don't just teach selling," says Priya Iyer, CHRO of a leading technology firm in Bangalore. "They transform how our teams show up--confident, prepared, and aligned with the customer. We've seen a 50% spike in performance across three regions." Sharma's flagship corporate training engagements focus on aligning sales behaviors with organizational KPIs, guiding participants through the sales process with tools drawn from authoritative selling, negotiation psychology, and key account management. National Impact Through NLP Limited As the driving force behind NLP Limited, Sharma has positioned the company as India's leading training firm for sales professionals, salespeople, and emerging sales consultants. The firm works with companies all over the country, including major accounts in Ahmedabad, Hyderabad, and Chennai, delivering programs tailored to local and global business dynamics. In recognition of its high impact, NLP Limited has expanded its partnerships with top training companies in India, and now delivers programs across Southeast Asia, the Middle East, and Africa. Changing the Sales Career Narrative For young professionals entering the sales industry, Sharma's influence goes beyond performance. His mentorship and leadership coaching have helped hundreds of individuals rise from entry-level sales roles to senior business development and key account positions. His programs include structured certifications, leadership accelerators, and personalized coaching modules designed to foster high-value conversations, overcome objections, and create enduring client relationships. Recognitions and Rankings -Ranked among the Top 5 Sales Trainers Worldwide -Creator of the MARK Model, used by hundreds of global organizations -Recognized Top Sales Influencer and Motivational Keynote Speaker -Trusted by CEOs, CHROs, and L & D leaders across 15+ industries - India's foremost expert in sales psychology, NLP, and consultative selling The Future of Sales in India: Installed from Within Rajiv Sharma's work reflects a deeper shift in the Indian business landscape--where sales is no longer seen as a transaction, but as a trusted dialogue between value creators and solution seekers. His programs install this mindset from the inside out. As more companies seek sustainable growth in a volatile global economy, Sharma's message resonates clearly: when you build the right sales culture, the numbers take care of themselves. "You don't need more salespeople," Sharma says. "You need more people who believe in what they're selling, feel congruent doing it, and are trained to lead clients to decisions that create success--for everyone." About Rajiv Sharma Rajiv Sharma is a globally ranked sales trainer, leadership coach, and motivational speaker based in India. As the founder of NLP Limited, he has trained professionals in over 45 countries and developed the MARK Model--used by thousands of teams to achieve high-impact sales results. Sharma is a regular keynote speaker at global leadership summits and consults with CXOs on building scalable, emotionally intelligent, sales-driven cultures. Contact for Media Inquiries